Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD

3.46  -0.14 (-3.76%)

After market: 3.7499 +0.29 (+8.38%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to BTMD. BTMD was compared to 195 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make BTMD a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BTMD was profitable.
BTMD had a positive operating cash flow in the past year.
BTMD had positive earnings in 4 of the past 5 years.
BTMD had a positive operating cash flow in 4 of the past 5 years.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

BTMD has a Return On Assets of 13.68%. This is amongst the best in the industry. BTMD outperforms 95.94% of its industry peers.
The Return On Invested Capital of BTMD (43.56%) is better than 98.98% of its industry peers.
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROIC 43.56%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

The Profit Margin of BTMD (6.85%) is better than 85.28% of its industry peers.
In the last couple of years the Profit Margin of BTMD has declined.
With an excellent Operating Margin value of 16.78%, BTMD belongs to the best of the industry, outperforming 85.79% of the companies in the same industry.
In the last couple of years the Operating Margin of BTMD has declined.
With a decent Gross Margin value of 71.27%, BTMD is doing good in the industry, outperforming 79.19% of the companies in the same industry.
BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 2.83 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a better Altman-Z score (2.83) than 75.13% of its industry peers.
BTMD has a debt to FCF ratio of 4.81. This is a neutral value as BTMD would need 4.81 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.81, BTMD belongs to the top of the industry, outperforming 83.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Altman-Z 2.83
ROIC/WACC4.45
WACC9.79%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.42 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD has a worse Current ratio (1.42) than 69.54% of its industry peers.
A Quick Ratio of 1.14 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD has a worse Quick ratio (1.14) than 71.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.14
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 490.91%, which is quite impressive.
Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
Looking at the last year, BTMD shows a very strong growth in Revenue. The Revenue has grown by 31.42%.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%

3.2 Future

The Earnings Per Share is expected to grow by 48.55% on average over the next years. This is a very strong growth
Based on estimates for the next years, BTMD will show a quite strong growth in Revenue. The Revenue will grow by 9.68% on average per year.
EPS Next Y170.45%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.55%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.68%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

10

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.32, the valuation of BTMD can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 96.95% of the companies listed in the same industry.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 26.25, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 7.02, which indicates a rather cheap valuation of BTMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 92.89% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, BTMD is valued rather cheaply.
Industry RankSector Rank
PE 5.32
Fwd PE 7.02
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 91.37% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaply inside the industry as 97.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.79
EV/EBITDA 6.88
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
BTMD's earnings are expected to grow with 49.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y49.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTE CORP -A

NASDAQ:BTMD (5/30/2025, 8:00:01 PM)

After market: 3.7499 +0.29 (+8.38%)

3.46

-0.14 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners67.42%
Inst Owner Change-7.92%
Ins Owners27.6%
Ins Owner Change8.21%
Market Cap175.11M
Analysts83.33
Price Target7.62 (120.23%)
Short Float %3.1%
Short Ratio3.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)228.05%
Min EPS beat(2)-1.96%
Max EPS beat(2)458.07%
EPS beat(4)2
Avg EPS beat(4)111.48%
Min EPS beat(4)-269.68%
Max EPS beat(4)458.07%
EPS beat(8)4
Avg EPS beat(8)19.41%
EPS beat(12)6
Avg EPS beat(12)-81.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.66%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)3
Avg Revenue beat(8)-1.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.05%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.93%
EPS NQ rev (1m)-23.24%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)45.83%
EPS NY rev (3m)2.79%
Revenue NQ rev (1m)-2.45%
Revenue NQ rev (3m)-11.64%
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-9.91%
Valuation
Industry RankSector Rank
PE 5.32
Fwd PE 7.02
P/S 0.71
P/FCF 4.79
P/OCF 3.95
P/B N/A
P/tB N/A
EV/EBITDA 6.88
EPS(TTM)0.65
EY18.79%
EPS(NY)0.49
Fwd EY14.25%
FCF(TTM)0.72
FCFY20.89%
OCF(TTM)0.88
OCFY25.32%
SpS4.86
BVpS-1.78
TBVpS-2.07
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROCE 55.13%
ROIC 43.56%
ROICexc 98.25%
ROICexgc 177.09%
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
FCFM 14.86%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Debt/EBITDA 3.22
Cap/Depr 210.54%
Cap/Sales 3.15%
Interest Coverage 4.43
Cash Conversion 98.57%
Profit Quality 216.82%
Current Ratio 1.42
Quick Ratio 1.14
Altman-Z 2.83
F-Score6
WACC9.79%
ROIC/WACC4.45
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
EPS Next Y170.45%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.55%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.68%
EBIT growth 1Y32.35%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y18.95%
FCF growth 1Y849.75%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y1512.04%
OCF growth 3Y10.29%
OCF growth 5Y12.28%